Background: Positron emission tomography (PET) studies in major depressive disorder (MDD) have reported higher serotonin 1A (5-HT 1A ) autoreceptor binding in the raphe. In males, the difference is so large that it can potentially be used as the first biological marker for MDD. However, the raphe includes several nuclei, which project to different regions of the brain and spinal cord and may be differentially involved in disease. We aimed to identify 5-HT 1A differences in individual raphe nuclei using PET in order to determine whether use of subnuclei would provide greater sensitivity and specificity of diagnosing MDD.
INTRODUCTION
Serotonin (5-HT) dysfunction is implicated in the pathogenesis of major depressive disorder (MDD). Many studies of MDD have focused on serotonin neuron cell bodies that project to the central nervous system. These cells are found in the brainstem raphe nuclei (Hornung, 2003) . Serotonin release by raphe nuclei is regulated by somatodendritic 5-HT 1A autoreceptors (de Montigny & Blier, 1984; Pineyro & Blier, 1999 ) that inhibit cell firing. Greater 5-HT 1A expression in raphe nuclei is therefore thought to cause a depletion of serotonin elsewhere in the brain, linking increased levels of 5-HT 1A to MDD pathophysiology. Postmortem studies have shown that this effect is especially pronounced in the dorsal raphe nucleus (DRN) (Boldrini, Underwood, Mann, & Arango, 2008) .
Positron emission tomography (PET) imaging allows examination of 5-HT 1A in vivo, and several key findings have been made in the DRN.
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c 2018 Wiley Periodicals, Inc. 411 wileyonlinelibrary.com/journal/da F I G U R E 1 Schematic of individual raphe nuclei, adapted from Son et al. (2012) . DRN: dorsal raphe nucleus; MRN: median raphe nucleus; RPo: raphe pontis; RMg: raphe magnus; ROb: raphe obscurus; RPa: raphe pallidus. Caudal linear nucleus is not shown Using the selective 5-HT 1A antagonist [ 11 C]-WAY100635 (Forster et al., 1995) , we previously reported the presence of higher 5-HT 1A autoreceptor binding in the DRN in MDD compared to healthy volunteers (HV) as measured by BP F -the amount of available receptors times the affinity of those receptors for the tracer (Parsey et al., 2010; . We also found that greater 5-HT 1A BP F in the DRN is a sensitive (81.7%) and specific (84.8%) diagnostic marker of MDD in males (Kaufman et al., 2015) .
However, the resolution of a single PET imaging study generally prevents distinguishing the DRN from other nuclei of the raphe. Thus, even though many PET studies implicate the DRN, they may in fact be imaging the raphe as a whole. This has been true for our own studies, as we previously delineated the DRN by drawing an ellipse around an area of high 5-HT 1A density in the brainstem (Kaufman et al., 2015; Miller et al., 2013; Parsey et al., 2010; .
Other studies have drawn a sphere in the midbrain only (Drevets, 2000; Hahn et al., 2010; Kraus et al., 2012) . Although this likely includes DRN, it may also include nearby raphe nuclei such as the median raphe nucleus (MRN). By combining 5-HT 1A binding in the entire midbrain or pontine region, we may be missing critical differences related to mood disorders that reflect different functional roles of these raphe subdivisions. Other raphe nuclei include the MRN, caudal linear nucleus (CLN), raphe pontis (RPo), raphe magnus (RMg), raphe pallidus (RPa), and raphe obscurus (ROb), shown in Figure 1 . Neurons from CLN, DRN, and MRN project to the brain, whereas RPo, RMg, RPa, and ROb project to spinal cord (Hornung, 2003) .
To identify individual raphe nuclei requires higher resolution and image contrast than generally observed in a single PET scan. To (Holmes et al., 1998) autoreceptor binding in medication-free MDD and HV. We hypothesized that 5-HT 1A BP F in the DRN and MRN would be higher in MDD relative to HV and would serve as a more accurate biomarker than the entire raphe, as these two nuclei send projections to forebrain areas known to be involved in MDD. As RMg innervates the spinal cord and serves sensorimotor functions, we hypothesized no difference in this region. Our previous work has shown that differences in raphe 5-HT 1A binding between MDD and HV are greater in men than in women (Kaufman et al., 2015) , and postmortem studies have also shown sex differences in binding (Boldrini et al., 2008) . To best capture differences, we focused on men in this study.
An objective biomarker for MDD has been highly sought after for decades (Kapur, Phillips, & Insel, 2012; Young et al., 2016) . For a robust estimate of BP F diagnosis classification threshold, we calculated receiver operating characteristic (ROC) curves using an expanded simulated dataset based on each subject's BP F value and a calculated standard error (SE) measurement of BP F .
MATERIALS AND METHODS

Participants
The data used in this study were acquired under a protocol approved 
absence of psychosis, schizophrenia, or bipolar disorder, and (8) capacity to provide informed consent. Inclusion criteria for controls were similar, except for (1) absence of an axis I disorder, and (2) absence of a first degree relative with a history of a mood or psychotic disorder. Screening was verified via history, physical exams, and routine blood and urine tests.
Radiochemistry, input function measures, and image acquisition and analysis
[ 11 C]-WAY100635 preparation, as well as measurement of arterial input function, metabolites, and plasma-free fraction (f p ) was performed as previously described (Parsey et al., 2000) . Magnetic resonance imaging (MRI) and PET data were acquired as previously described (Parsey et al., 2010) . 
Derivation of outcome measures
Regional distribution volumes for 11 C-WAY100635 were derived as described previously (Parsey et al., 2010) . The closest measure to in vitro binding potential for PET is BP F , or the product of available receptor density (B avail , nM per gram of tissue) and affinity (1/K D , nM per mL of brain). We have described optimal modeling used to calculate this measure elsewhere (Parsey et al., 2000) ; briefly, time activity curves (TACs) measured from PET scans were fit to a two tissue compartment model with plasma-to-tissue rate constants constrained to that of the cerebellar white matter, using an arterial input function. The last point in one patient's TAC for the MRN was removed as their BP F with that point included was millions of mL/cc, much higher than is physiologically plausible. SEs of BP F values were calculated using a bootstrapping technique that incorporates errors in plasma, metabolite, and brain data (Ogden & Tarpey, 2006) .
Subdivision of the raphe
Parametric binding potential (BP F ) maps were generated at each voxel from 52 PET scans of HV from a previous study using basis pursuit (Gunn, Gunn, Turkheimer, Aston, & Cunningham, 2002 ) (see Fig. 2 ), a data driven method that still allows for modeling considerations such as compartment modeling and reference regions (Gunn et al., 2002) .
This makes it well suited for a voxel analysis. A region-growing technique was used on an averaged BP F image to identify the raphe nuclei.
Seeds were manually placed in regions of the raphe that showed high focal binding, and a hybrid level-set method was employed to delineate the nuclei. Basically, this technique iteratively grows and adjusts the boundaries of a given region from the manually placed seed until the standard deviation inside the region is significantly different from the space surrounding the region (Zhang, Matuszewski, Shark, & Moore, 2008) . This method yielded three loci, which we determined to correspond to DRN, MRN, and RMg by comparison to an atlas. These nuclei had volumes of 168, 160, and 280 mm 3 , respectively. Since DRN and MRN both project to the forebrain, we defined an additional region of interest that encompassed both nuclei. All nuclei were identified as binary regions on an image in standard space, and treated as a template image that was nonlinearly warped to individual participants through their associated MRI image using the Advanced Normalization Toolbox (Avants et al., 2011) . Proper warping and alignment of the atlas containing the raphe regions to individual participant MRIs was visually checked and validated by a trained technician. With the raphe nuclei defined for each subject, BP F was calculated within each region as described above.
Statistical analysis
A linear mixed model with weights and two weighted linear regression models were used to compare raphe nucleus values between HV and MDD groups in individual nucleus regions of interest (ROIs) and combined nucleus ROIs, respectively. Log-transformation was applied to BP F to normalize the distribution to meet model assumptions.
Weights were defined as the reciprocal of SE squared for each outcome. The two-way interaction term between subject group (HV vs.
MDD) and nuclei was considered. Dependence structures for modeling the correlation among nuclei from the same subject were selected based on Akaike Information Criteria. Compound symmetry was used as the covariance structure in the final linear mixed model. P-values less than .05 were considered statistically significant and analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC). Post hoc t tests were then carried out for group differences in each individual nucleus, and Bonferroni correction was used for to correct for multiple comparisons.
To examine whether BP F thresholds could distinguish someone with MDD versus someone without, ROC analysis was performed using the BP F values of each nucleus. In order to approximate real-world BP F values in a generalized sample, 1,000 simulated values were generated for each subject. These values were sampled from log normal distributions with mean and standard deviation determined by the subject's BP F and SE of BP F . Then, each of the 1,000 simulated data points were fit to a logistic function with BP F as a predictive variable and the probability of having MDD as the outcome variable (defined as the log odds of having MDD for a given BP F ). Using logistic regression outputs, ROCs were constructed, and Youden's index (defined as the point maximizing the sum of sensitivity and specificity) was used to determine which BP F threshold could separate those with and without MDD with the greatest predictive performance. Averages and standard deviations of the area under the curve (AUC) and BP F cutoff thresholds were calculated.
A one-sided z-test for each participant was performed using simulated data, where the null hypothesis was that the participant's measured mean BP F value was less than the threshold value (i.e., the patient does not have MDD). If the null hypothesis was rejected, the participant was classified as having MDD. A confusion matrix was constructed comparing the output of our classification system to the number of true positives (patients who were correctly identified as having MDD) and true negatives (HVs who were correctly identified as not having MDD). Sensitivity was calculated by dividing the number of participants the algorithm classified as having MDD by the number of true positives, whereas specificity was calculated by dividing the number of participants classified as HV divided by the number of true negatives.
RESULTS
Comparison of raphe nuclei
Patient demographics are listed in 
Diagnosis classification using nuclei BP F
ROC curve values for all nuclei can be found in Table 3 . The DRN and MRN combined had the best performance, with a sensitivity of 94% and a specificity of 84% and an average AUC of 93%. The worst was RMg, with a specificity of 94% but a sensitivity of only 32% and an average AUC of 63% (Fig. 5 ).
DISCUSSION
We have improved our raphe-based biomarker for MDD (Kaufman et al., 2015) as having MDD or not, using ROC curves derived from simulated datasets to classify participants and evaluate diagnostic accuracy. As the simulated datasets contained BP F values that fell within the SE for each participant, they represented a generalized expansion of our measured data. As greater SE represents higher uncertainty regarding the measure, the simulated BP F values will be sampled from a greater range for those with higher SE. Thus, we can realistically estimate an underlying population for each subject. As we did not have an external sample to test these thresholds, this analysis provides a robust method for testing accuracy that can yield greater predictive potential than delineating a diagnostic threshold from our dataset alone.
In terms of sensitivity and specificity, binding in the RMg performs much worse than the combination of DRN and MRN or DRN alonein fact, greatest diagnostic accuracy can be obtained by grouping DRN and MRN and omitting RMg, which resulted in 94% sensitivity and 84% specificity, an increase from our previous finding of 81.7% sensitivity and 84.8% specificity over the raphe nucleus as a whole (Kaufman et al., 2015) . This corresponds to what is known physiologically. The greatest evidence for 5-HT 1A mediated autoregulation has been found in the DRN and MRN (Boldrini et al., 2008; Hopwood & Stamford, 2001 ).
Moreover, DRN and MRN provide the majority of serotonergic fibers to the brain, whereas RMg projects to the spinal cord (Hornung, 2003) .
As MDD is considered a disorder of the brain, one would expect greater dysregulation in the DRN and MRN of depressed patients, particularly in the DRN, which supplies the majority of forebrain structures and regions such as the amygdala (Hornung, 2003) .
We are not the first to examine individual raphe nuclei in vivo via PET imaging; others have delineated individual nuclei using the serotonin transporter (5-HTT) (Fazio et al., 2016; Son et al., 2014 ).
An advantage to our approach of using 5-HT 1A as opposed to 5-HTT is that 5-HT 1A has a more specific differential distribution across the raphe nuclei (Stockmeier, Shapiro, Haycock, Thompson, & Lowy, 1996) , which allows us to target somatodendritic autoreceptors with greater precision. Using this sensitive measure we show that 5- a Note: Sensitivity and specificity were calculated by applying the thresholds decided based on Youden's index onto the original data, not onto the simulated data.
addition, this biomarker is objectively observable. An accurate and objective biomarker can be used for further examination of the disorder, including exploring subdiagnostic categories, evaluating more targeted treatment strategies, and identifying increased risk for MDD (Peterson & Weissman, 2011) . Though PET imaging is expensive, the biological understanding it offers could aid researchers and clinicians substantially in understanding the neurobiological underpinnings of this disorder, which can improve treatment decisions, formulation of new research questions, and rational drug design. Importantly, a reliable PET-based biomarker using PET can also allow us to search for other, less costly surrogate markers that offer similar information.
However, to have more confidence in this diagnostic accuracy will require validating the thresholds in an independent cohort with a larger sample size.
F I G U R E 5
Receiver operating characteristic (ROC) curves for BP F thresholds separating participants with and without MDD in raphe magnus and dorsal and median raphe combined. AUC: area under the curve, followed by 95% confidence interval. Of all the nuclei examined, raphe magnus performs the worst as a diagnostic test (right), whereas dorsal and median raphe nucleus combined performs the best (left)
Anatomical projections of the DRN have been studied in rodents and monkeys (Wilson & Molliver, 1991a , 1991b . The rostral portion of the DRN contains the dorsal, ventral, ventrolateral, and interfascicular subnuclei, whereas the caudal DRN contains the caudal and interfascicular subnuclei. Tract-tracing studies indicated that neurons located in the rostral portion of the DRN project to caudateputamen and substantia nigra, whereas caudal DRN neurons project to the hippocampus, amygdala, and locus coeruleus in rodents (Azmitia, 1981; Imai, Steindler, & Kitai, 1986) , and to the pineal gland in the golden hamster (Leander, Vrang, & Moller, 1998) . Neurons of the medial DRN project to the medial PFC in the rat (Van Bockstaele, Biswas, & Pickel, 1993) . The ventromedial and ventrolateral DRN project to the thalamus (Gonzalo-Ruiz, Lieberman, & Sanz-Anquela, 1995) and olfactory cortex (Datiche, Luppi, & Cattarelli, 1995) . In macaque monkeys, the dorsal DRN is reported to have dorsolateral PFC as its cortical target (Charara & Parent, 1998; Wilson & Molliver, 1991b) .
Given this information, and that postmortem studies have shown higher 5-HT 1A binding in MDD at the most rostral level of the DRN (Boldrini et al., 2008) , it is surprising that DRN was not a better MDD biomarker than DRN and MRN combined. In fact, when comparing individual nuclei, the greatest difference between groups is found in the DRN. This is supported by previous postmortem data. Tryptophan hydroxylase immunoreactivity, corresponding to serotonergic neurons, is reported to be higher in MDD suicide victims compared with controls in the DRN, but not in the MRN (Boldrini, Underwood, Mann, & Arango, 2005) .
However, with PET imaging, small regions such as individual nuclei are more susceptible to noise and partial volume effects. MRN was most affected by noise (possibly due to overlap with the caudal tail of DRN (Hornung, 2003) that exacerbated partial volume effects), but all three individual nuclei were noisier than the DRN + MRN and the entire raphe (Fig. 4 ). Therefore on a practical level, larger ROIs are better for discrimination. However, the RN as a whole included the nonspecific RMg, which decreased our ability to differentiate HV from Although there was no difference between groups in 5-HT 1A density in RMg, there are individual patients with MDD with particularly high binding in this region (Fig. 4) . This may have clinical relevance on an individual level. The RMg plays a role in analgesia and pain perception; stimulation studies in MDD have revealed a lowered pain threshold relative to healthy comparisons (Boettger, Grossmann, & Bar, 2013; Klauenberg et al., 2008; Pinerua-Shuhaibar, Villalobos, Delgado, Rubio, & Suarez-Roca, 2011; Tikasz, Tourjman, Chalaye, Marchand, & Potvin, 2016; Zambito Marsala et al., 2015) . Indeed, 5-HT 1A activation may result in hyperalgesia (Zhang, Gao, Yang, Huang, & Wu, 2000) , perhaps through inhibition of centrally modulated analgesia. This could provide an explanation for known correlations between pain and depression severity (Brnabic, Lin, Monkul, Duenas, & Raskin, 2012; Brnabic, Raskin, Alev, Serap Monkul, & Lowry, 2012; Maneeton, Maneeton, & Srisurapanont, 2013; Robinson et al., 2013) . (Monti, 2010) .
A significant impediment to studying individual raphe nuclei is the spatial resolution of PET imaging. The full width half max of our scanner was 4.5 mm. Given the small size of these nuclei, our data will be susceptible to partial volume effects, which would decrease the apparent BP F of each nucleus. Partial volume correction can be performed, but these usually require an MRI-defined region-none exists for the raphe nucleus. This means that the differences we find in our study are likely underestimated; the finding of increased 5-HT 1A density in patients with MDD suggests that this is due to a physiological difference, irrespective of these effects.
Finally, since our aim was to highlight differences between raphe nuclei as a clinical tool, we focused our analysis on males as much larger group differences in 5-HT 1A binding are seen with them (Kaufman et al., 2015) . In addition, though we have previously collected data from female participants, we did not obtain information that we now know plays a role in serotonin function, such as menstrual cycle and hormone levels (Endicott, 1993) . Future analyses should include female participants with relevant covariates, particularly if there is a different distribution of 5-HT 1A receptors among different nuclei between sexes. This is especially important, as MDD is more prevalent in females (Kessler et al., 2003) .That being said, males with MDD still comprise millions of people (Karg et al., 2012) . Given the sex differences in MDD, studying both sexes independently is important in studying and eventually treating this disorder.
CONCLUSIONS
Using an averaged serotonin 1A binding map obtained through PET imaging, we have delineated three of the raphe nuclei and applied these region labels to individual scans. Group differences in 5-HT 1A are greatest when excluding the RMg from the raphe ROI, yielding a highly sensitive and specific biomarker. Across single nuclei, individuals with MDD have greater BP F than HV in the DRN, but not in the MRN or RMg. This accords well with the fact that DRN projects to forebrain areas implicated in MDD. Our findings may allow for more detailed future study of MDD symptomatology and its relation to different raphe nuclei.
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